Collegium Pharmaceutical’s (COLL) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Collegium Pharmaceutical (NASDAQ:COLL) in a report issued on Monday morning,Benzinga reports. HC Wainwright currently has a $50.00 target price on the specialty pharmaceutical company’s stock. HC Wainwright also issued estimates for Collegium Pharmaceutical’s Q1 2025 earnings at $1.20 EPS and Q2 2025 earnings at $1.48 EPS.

COLL has been the topic of several other research reports. Piper Sandler dropped their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 4th. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a research note on Friday, January 10th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $43.60.

Collegium Pharmaceutical Stock Down 0.6 %

Collegium Pharmaceutical stock opened at $29.96 on Monday. The stock has a market capitalization of $943.32 million, a price-to-earnings ratio of 12.91 and a beta of 0.99. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The stock has a 50 day moving average of $30.51 and a two-hundred day moving average of $32.52. Collegium Pharmaceutical has a twelve month low of $27.28 and a twelve month high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.09. The firm had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. As a group, research analysts expect that Collegium Pharmaceutical will post 5.62 earnings per share for the current year.

Insider Transactions at Collegium Pharmaceutical

In other news, EVP Shirley R. Kuhlmann sold 27,500 shares of the company’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $33.04, for a total value of $908,600.00. Following the sale, the executive vice president now directly owns 119,184 shares in the company, valued at $3,937,839.36. This represents a 18.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Colleen Tupper sold 1,949 shares of the company’s stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $30.00, for a total transaction of $58,470.00. Following the completion of the transaction, the chief financial officer now owns 177,195 shares in the company, valued at approximately $5,315,850. This trade represents a 1.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 109,193 shares of company stock valued at $3,243,594 in the last quarter. 3.98% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Collegium Pharmaceutical

Institutional investors and hedge funds have recently modified their holdings of the company. Nisa Investment Advisors LLC raised its holdings in Collegium Pharmaceutical by 14.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after acquiring an additional 316 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Collegium Pharmaceutical by 1.9% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,221 shares of the specialty pharmaceutical company’s stock valued at $522,000 after purchasing an additional 339 shares during the period. AlphaQuest LLC increased its stake in Collegium Pharmaceutical by 3.0% in the fourth quarter. AlphaQuest LLC now owns 12,780 shares of the specialty pharmaceutical company’s stock valued at $366,000 after purchasing an additional 374 shares during the last quarter. Foundry Partners LLC increased its stake in Collegium Pharmaceutical by 2.4% in the fourth quarter. Foundry Partners LLC now owns 16,162 shares of the specialty pharmaceutical company’s stock valued at $463,000 after purchasing an additional 381 shares during the last quarter. Finally, Gallacher Capital Management LLC lifted its position in Collegium Pharmaceutical by 3.3% during the fourth quarter. Gallacher Capital Management LLC now owns 14,571 shares of the specialty pharmaceutical company’s stock worth $417,000 after buying an additional 470 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.